Heterozygous RAD50 mutational status may be associated with breast cancer risk in the Finnish population [6, 7] but large case–control studies have not confirmed an overall association of RAD50 germline variants with breast cancer risk [8, 9, 10, 11]. This evidence concerns the gene RAD50 and breast carcinoma.